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Epigenetics, complex disease, and the brain
n general, epigenetics refers to the regulation
of DNA sequences that does not involve alteration of
their actual base composition. Transcription and numer-
ous other genomic functions are epigenetically con-
trolled via heritable, but potentially reversible, changes
in modification of DNA and histones (acetylation,
methylation, phosphorylation, etc),
1 and epigenomics is
the application of these processes across the genome. 
The normal functioning of genomes is tightly connected
to their epigenetic regulation, and epimutations can be
harmful in the presence of impeccable DNA sequences.
The epigenetic theory of complex non-Mendelian dis-
ease is based on three key postulates. Firstly, an organ-
ism's epigenetic status is far more dynamic than its DNA
sequence, and may be altered by a number of factors,
such as environment, developmental programs,
2 or even
as a result of stochasticity.
3 Secondly, certain epigenetic
signals may be inherited transgenerationally with DNA
sequence
4 and may account for heritability of some traits
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Psychiatric diseases place a tremendous burden on
affected individuals, their caregivers, and the health care
system. Although evidence exists for a strong inherited
component to many of these conditions, dedicated efforts
to identify DNA sequence-based causes have not been
exceptionally productive, and very few pharmacologic
treatment options are clinically available. Many features
of psychiatric diseases are consistent with an epigenetic
dysregulation, such as discordance of monozygotic twins,
late age of onset, parent-of-origin and sex effects, and
fluctuating disease course. In recent years, experimental
technologies have significantly advanced, permitting in-
depth studies of the epigenome and its role in mainte-
nance of normal genomic functions, as well as disease
etiopathogenesis. Here, we present an epigenetic expla-
nation for many characteristics of psychiatric disease,
review the current literature on the epigenetic mecha-
nisms involved in major psychosis, Alzheimer’s disease, and
autism spectrum disorders, and describe some future
directions in the field of psychiatric epigenomics.  
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5 Thirdly, epigenetic regulation is required
in the maintenance of proper genomic function, for
example, regulation of gene activity, inactivation of par-
asitic DNA elements, and chromosomal segregation.
6
Epigenetic factors greatly affect phenotype—even genes
that are free of mutations may become harmful if they
are not expressed at the appropriate time and at the
required level. Combined, these points provide a solid,
mechanistic basis for a cohesive interpretation of vari-
ous epidemiological, clinical, and molecular features of
complex diseases. 
The molecular epigenetic mechanisms are complex and
highly intertwined. At the most basic level, methyl
groups may be bound to cytosines at the C5 carbon, usu-
ally within cytosine/guanine dinucleotides (CpG), which
are established and maintained by the DNA methyl-
transferase (DNMT) family of enzymes. This is believed
to be the most stable epigenetic mark, due to the cova-
lent nature of the modification.
7 Additionally, another
DNA modification, hydroxymethylcytosine, has very
recently been discovered in Purkinje neurons and other
cells of the brain, and it may also play a role in epige-
netic regulation of neural function.
8
DNA is wrapped around octamers of basic histone pro-
teins, each consisting of a core and N-terminus, to form
nucleosomes. Numerous modifications of these proteins
influence the condensation of chromatin, which can be
open (transcriptionally active) or closed (inactive).
Histone acetyltransferases (HATs) acetylate lysine
residues on the N-terminal tail of histone proteins, neu-
tralizing the positive charge of the protein and decreas-
ing its affinity for DNA. As a result, the chromatin
relaxes and the transcription machinery gains access to
previously restricted sites.
9 Acetyl groups can be
removed by histone deacetylases (HDACs), resulting in
chromatin condensation and transcriptional inactiva-
tion.
10 The presence of an N-terminal methyl-CpG-
binding domain (MBD) allows proteins, such as methyl-
CpG-binding protein 2 (MeCP2), to bind methylated
sites on DNA and complex with HDACs and the core-
pressor SIN3A. The complex facilitates histone deacety-
lation and downstream gene silencing from the methy-
lated CpG site. Histone methylation can result in either
gene activation or repression, depending on the specific
lysine or arginine that is modified.
11 Another family of
enzymes, the histone demethylases, such as lysine-spe-
cific demethylase 1 (LSD1), are capable of removing this
methyl group from the lysine residues of histone and
nonhistone proteins.
12
A hallmark of non-Mendelian disease, discordance of
monozygotic (MZ) twins, has traditionally been attrib-
uted to differential environmental factors activating a
disease state in one of the genetically predisposed co-
twins
13; however, very few of these factors have been
identified. Alternately, MZ twin discordance may be due
to the partial stability of epigenetic factors, as disease-
relevant epigenetic dissimilarity can accumulate quite
readily between cotwins.
5,14,15 Another non-Mendelian
peculiarity, sexual dimorphism, is the differential sus-
ceptibility to a disease between males and females. It is
observed in many psychiatric conditions, such as
Alzheimer's disease, schizophrenia, alcoholism, and
mood and anxiety disorders.
16Although the exact mech-
anism by which they predispose or protect from a dis-
ease is currently unknown, there is a great deal of evi-
dence that sex hormones exert control of gene
expression via epigenetic modifications; thus it is hypoth-
esized that sexual dimorphism in many disease states
may be the result of sex hormone-induced differences in
the epigenetic status of key genes.
17,18 Furthermore, the
degree of risk for acquiring certain complex diseases
may depend on the sex of the affected parent, as in
schizophrenia,
19 Alzheimer's disease (AD),
20 autism,
21
and bipolar disorder (BD).
22 Genomic imprinting, an epi-
genetic mechanism in which differential epigenetic mod-
ification of genes occurs depending on their parental ori-
gin,
23 is thought to be the source of such parent-of-origin
effects. Diseases affecting cell growth, development, and
behavior may result from disruption of the normal
imprinting pattern.
24
In the epigenetic model of complex disease, it is assumed
that a primary epigenetic disruption takes place during
the maturation of the germline, and this pre-epimutation
increases an organism's risk of acquiring a disease. The
Basic research
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Selected abbreviations and acronyms
AD Alzheimer's disease
ASD autism spectrum disorders
BD bipolar disorder
DNMT DNA methyltransferase
GABA -aminobutyric acid
GAD glutamate decarboxylase
HDAC histone deacetylase
LOAD late-onset Alzheimer's disease
RTT Rett syndrome
SZ schizophrenia
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ficient to cause the disease itself, but with time, perhaps
even decades, small misregulations add up until a thresh-
old is crossed and the individual experiences phenotypic
changes that meet diagnostic criteria for a clinical disor-
der. The age of disease onset may depend on the effects
of tissue differentiation, stochastic factors, hormones, and
likely some external environmental factors (nutrition,
infections, medications, addictions, etc).
6,25,26 Severity of
epimutations may fluctuate over time, due to their
reversible nature, known to clinicians as “remission” and
“relapse.” It is also possible that epimutations may
regress back to the norm with aging, which presents par-
tial recovery, eg, reduction of psychopathology in elderly
psychiatric patients.
Although there are very few studies investigating the
role of epigenetic factors in psychiatric diseases, there is
an increasing body of experimental evidence that epi-
genetic signals play a critical role in neuronal develop-
ment, differentiation, and communication, as well as
synaptic plasticity in general
27; these processes are fun-
damental for normal brain activity, such as learning and
memory.
28,29 The known epigenetic modifiers, Polycomb
(PcG), and Trithorax (TrxG) proteins, have been shown
to influence synaptic plasticity,
30,31 and cascade activation
during memory formation in the mitogen activated pro-
tein kinase (MAPK) pathway appears to trigger H3K14
acetylation.
32 Additionally, pharmacologic inhibitors of
epigenetic processes have had documented effects on
long-term potentiation (LTP), an increase in efficiency
of synaptic transmission, in the mammalian brain.
DNMT inhibitors, such as zebularine, impair induction
of LTP in mouse hippocampus,
33 while HDAC inhibitors
(HDACi), such as sodium butyrate and trichostatin A
(TSA), have been shown to enhance LTP in rat hip-
pocampus
32 and amygdala.
34 Taken together, this theo-
retical and experimental evidence suggest that epige-
netic regulation is essential for neural and brain
functioning, and putative epimutations may play a role
in etiopathogenesis of complex psychiatric disease. 
Psychiatric epigenetics and epigenomics
Major psychosis
Major psychosis is a classification that encompasses both
schizophrenia (SZ) and BD—two conditions that seem
to be related etiologically.
35 SZ is a multifactorial disease
characterized by disordered thinking and concentration
that results in psychotic thoughts (delusions and hallu-
cinations), inappropriate emotional responses, erratic
behavior, as well as social and occupational deteriora-
tion,
36 while BD represents a category of mood disorders,
in which affected individuals experience episodes of
mania or hypomania interspersed with periods of
depression, and may also suffer from delusions and hal-
lucinations. Thus far, traditional gene- and environment-
based approaches have not been very successful in deci-
phering the clinical, molecular, and epidemiological
aspects of psychosis, such as MZ discordance (41% to
65% for SZ,
37 ~60% BD
38), sexual dimorphism, parent-
of-origin effects, fluctuating disease course with periods
of remission and relapse, and peaks of susceptibility to
the disease that correspond to periods of major hor-
monal changes in the organism.
25 Classically, psychosis
research was aimed at defining genetic and environ-
mental risk factors, but despite significant evidence of
a heritable component derived from twin and adoption
studies,
39,40 many molecular genetic findings have not
been replicated, and significant heterogeneity and small
effect sizes are thought to plague genetic association
studies.
41
Recently, the first epigenomic study of major psychosis
utilizing CpG-island microarrays was released by Mill et
al,
42 providing a large-scale overview of DNA methylation
differences in the brain associated with SZ and BD. DNA
extracted from the frontal cortex was subjected to enrich-
ment of the unmethylated fraction using the methylation-
sensitive restriction enzymes, and adaptor ligation cou-
pled with PCR amplification. The amplicons (multiple
copies of the unmethylated genomic DNA) were interro-
gated on 12 192 feature CpG-island microarrays. The data
was normalized, assigned raw P values based on a t sta-
tistic, and then converted to false discovery rates (FDR).
Indeed, in cortex they discovered differences at loci
involved in glutamatergic and γ-aminobutyric acid
(GABA)-ergic neurotransmission, brain development,
mitochondrial function, stress response, and other disease-
related functions, many of which correspond to psychosis-
related changes in steady-state mRNA. In relation to the
glutamatergic hypothesis, a lower degree of DNA methy-
lation was observed in SZ and combined male psychosis
(SZ and BD) samples at two glutamate receptor genes,
NR3B and the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor (AMPA) receptor-sub-
unit gene GRIA2; the dysregulation of AMPA and N-
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DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 27methyl-D-aspartic acid (NMDA) receptors is an etiolog-
ical component of major psychosis, and it has been shown
that GRIA2 expression is altered in the prefrontal cortex
and striatum of SZ patients.
43 Hypomethylation was also
detected at the vesicular glutamate transporter
(VGLUT2) in SZ females, and at secretogranin II
(SCG2), which encodes a neuronal vesicle protein that
stimulates glutamate release. A higher degree of methy-
lation was observed in SZ females at VGLUT1, a trans-
porter protein that is downregulated in SZ brains,
44 and
the glutaminase enzyme, GLS2, in SZ males, which has
previously been shown to exhibit altered expression in
cases of SZ.
45 In synergy with glutamatergic pathways,
GABAergic pathways also show dysregulation in cases of
major psychosis. Detected disruptions in such pathways
included hypermethylation at the RNA-binding regula-
tor of GABA(B) receptors, MARLIN-1, in SZ, BD, and
psychosis females, the G protein-coupled inwardly recti-
fying potassium channel linked to GABA neurotrans-
mission, KCNJ6, in SZ and psychosis males, as well as the
HELT locus in SZ and BD females, which is known to
determine GABAergic over glutamatergic neuronal fate
in the mesencephalon. Several other intriguing loci were
highlighted, such as the hypermethylation at WNT1, a
gene critical for neurodevelopment that is differentially
expressed in SZ brains,
46 in females affected with major
psychosis, and at AUTS2 in SZ males, which spans a
translocation breakpoint associated with autism and men-
tal retardation. A highly significant hypermethylation was
detected in both male and female samples at two loci:
RPP21, which encodes a component of ribonuclease P, a
complex that forms t-RNA molecules via 5’-end cleavage,
and KEL, which encodes the Kell blood-group glycopro-
tein and causes McLeod Syndrome when incorrectly
expressed; SZ symptoms are manifested as part of
McLeod Syndrome. Network and gene ontology (GO)
analyses were performed in order to determine relation-
ships between the functionally linked pathways from the
microarray dataset. The network analysis revealed a lower
degree of modularity of DNA methylation “nodes” in the
major psychosis samples, indicating that there is some
degree of systemic epigenetic dysregulation involved in
the disorder. From the GO analysis, several categories
were highlighted, including those involved in epigenetic
processes, transcription, and development, as well as brain
development in female BD and SZ samples, and in those
related to stress response in male BD samples.
46To date,
this is the largest and most comprehensive epigenomic
study of major psychosis—the data presented supports
epigenetic mechanisms underlying broader hypotheses of
major psychosis and uncovers some new avenues for
future exploration.
Both SZ and BD have also been examined using the
candidate gene approach, as epigenetic downregulation
of genes is emerging as a possible underlying mechanism
of the GABAergic neuronal dysfunction in SZ. One of
the more intensively investigated SZ-related genes is
RELN, which is involved in neuronal development and
cell signaling, and has been found to be hypermethylated
in cases of SZ.
47 However, no differences were observed
at this locus in a replication attempt,
46,48 and the focus
seems to be shifting to other candidate genes, namely the
67 kDa glutamate decarboxylase (GAD67, aka GAD1)
and DNMT1. GAD67 catalyzes the conversion of glu-
tamic acid to GABA. In cases of SZ, the levels of this
enzyme and several others involved in GABAergic neu-
rotransmission, such as GAD65 and GABA plasma
membrane transporter-1 (GAT-1), display decreased
mRNA levels, as determined by real-time quantitative
polymerase chain reaction (qPCR) and in situ hybridiza-
tion.
49-52 In addition to aberrant methylation at this locus,
an analysis of the microarray collection of the National
Brain Databank (USA) has shown that decreased
GAD67 mRNA levels strongly correlated with upregu-
lated HDAC1 in the prefrontal cortices of SZ subjects.
53
Oddly enough, at the GAD67 promoter, SZ patients
have been shown to display an ~8-fold deficit in repres-
sive chromatin-associated DNA methylation.
54 In the
prefrontal cortex of 41 SZ patients, another histone
modification, H3-(methyl)arginine 17 (H3meR17) was
found to exceed control levels by 30%, and this was
associated with downregulated metabolic gene expres-
sion.
55 So, while it is apparent that histone modifications
are involved in the development of SZ, their exact mech-
anism is not entirely clear. Hypermethylation of GAD67
is believed to occur via DNMT1,
56,57 a maintenance
methyltransferase enzyme that is upregulated in the
GABAergic neurons and peripheral blood lymphocytes
of SZ patients, along with the de novo methyltransferase,
DNMT3a.
56,58 Interestingly, nicotine has been shown to
decrease DNMT1 mRNA expression in cortical and hip-
pocampal GABAergic neurons in mice—this decrease
results in GAD67 promoter demethylation, and is
inversely related to an upregulation of cortical GAD67
protein.
59 This information is highly relevant, as SZ
patients tend to smoke tobacco at a rate that is 2- to 4-
Basic research
28
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 28fold higher than in the general population,
60 and are pos-
sibly drawn to the nicotine content for its effects on the
aforementioned pathway.
Less information is available on BD; genomic imprinting
has been suggested by statistical genetics, but molecular
approaches have not yielded the imprinted disease
genes.
61A recent study applied methylation-sensitive rep-
resentational difference analysis (MS-RDA) to lym-
phoblastoid cells derived from twins discordant for BD.
62
One detected gene, named peptidylprolyl isomerase E-
like (PPIEL), was hypomethylated in BD-affected twins,
while a region of the spermine synthase (SMS) gene was
hypermethylated versus unaffected twins; it has yet to be
determined if either of these regions are biologically and
functionally significant. In combined studies of epige-
netics and DNA sequence, some interesting develop-
ments have been observed. It has recently been shown
that rare G variants of a G/A polymorphism in the potas-
sium chloride co-transporter 3 gene (SLC12A6) may rep-
resent risk factors for BD.
63 Eventually, it was discovered
that variants containing the G allele were methylated at
the adjacent cytosine, and this accompanied a decrease
in gene expression in human lymphocytes.
64This hints at
a functional link between epigenetics and genetic varia-
tion, and the association with BD is believable, as
SLC12A6 mutations underlie another psychiatric disor-
der, Andermann syndrome, which is an autosomal reces-
sive motor-sensory neuropathy associated with develop-
mental and neurodegenerative defects.
65 It is interesting
to note that BD provides a unique opportunity to inves-
tigate epigenetic variation between two extreme forms
of the same disease—depression and mania. A study
design of this variety would unfortunately be limited to
the use of peripheral blood, buccal epithelial cells, and
fibroblasts as experimental tissues, but nonetheless, it
would be incredibly interesting to determine the state of
the epigenome during manic and depressive states, in the
same individual when the same genetic and environ-
mental impacts are present.
Alzheimer’s disease
AD is a neurodegenerative disorder and the most com-
mon form of dementia in the elderly; it is characterized
by the accumulation of intracellular neurofibrillary tan-
gles (NFT) and extracellular amyloid plaques in the
brain.
66 AD often presents with psychiatric symptoms
such as memory loss, mood swings, and irritability that
increase in severity as the disease progresses. While the
phenotype of this condition is well documented, the mol-
ecular mechanisms largely remain unknown. The major-
ity of AD research focuses on dysregulation of fibers and
proteins, such as epsilon4 allele of apolipoprotein E
(APOE), but little ground has been gained in regards to
determining the actual origins of their dysfunction.
67 In
the rare early-onset form of AD (EOAD), genetic fac-
tors play a more defined role, with mutations in amyloid-
beta precursor protein (APP) and the presenilin genes
(PSEN1, PSEN2) showing a clear connection to the dis-
ease.
68 However, since EOAD does not represent the
majority of all cases, accounting for only ~5% of the
total,
69 this genetic model is not normally applicable.
Similar to other complex diseases, late-onset AD
(LOAD), the more common form of the illness that
affects individuals over 65 years of age, demonstrates a
considerable number of non-Mendelian features. Some
of these anomalies include dominance of sporadic over
familial cases,
70 discordance of MZ twins,
71 differential
susceptibility and course of illness in males and
females,
16,18 parent-of-origin effects
72 and, clearly, the late
age of onset that is not easily explained by genetic causes
alone. Consistent with the epigenetic hypothesis, abnor-
mal levels of folate and homocysteine, signs of dysreg-
ulated methylation maintenance, have been detected in
the brain of AD subjects. LOAD is a particularly inter-
esting target from the epigenetics of aging perspective,
as the epigenome may become deregulated in old age.
73
Using a MethyLight approach, it was shown that a large
number of genes increase in methylation with age in
control subjects, including several implicated in AD and
SZ (GAD1, PSEN1, BDNF, DRD2, GABRA2, HOXA1,
NTF3, LDLR, and S100A2), whereas Alu and other
repetitive elements showed a significant decrease in
DNA methylation that was limited to the first decade of
life.
74 Of the fifty loci investigated, two displayed signif-
icant changes in methylation status with age in AD sub-
jects: SORBS3 gained methylation over time and is
more likely to be methylated in AD patients, while
S100A2 displays a complex chronology, but results in a
slow, stochastic methylation decrease later in life (ibid).
SORBS3 encodes a neuronal/glial cell adhesion mole-
cule and S100A2 encodes a calcium binding protein from
the S100 family. As part of normal brain aging, S100A2
protein accumulates in corpora amylacea, or polyglu-
cosan bodies; subjects with neurodegenerative disorders
experience a much greater accumulation of corpora
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75 and this is consistent with the eventual
decrease in S100A2 methylation.
74
In a study dedicated to DNA methylation analysis of AD
candidate genes, it was found that the twelve analyzed loci
were epigenetically different in the brains of LOAD cases
versus controls, particularly at the locus for transcription
factor A (TFAM), a key activator of mitochondrial tran-
scription in mammals. Other candidates, such as PSEN1,
APOE, DNMT1, and MTHFR, displayed an enhanced
“distance” in LOAD subjects.
76This concept of distance is
part of the theory of “epigenetic drift,” in which an affected
individual has an epigenetic status at some gene(s) that is
distanced from the norm, and this distance increases with
age.
76 Of the CpG-rich regions analyzed, the majority were
unmethylated, and it appears possible that very small alter-
ations in methylation level could accumulate over time,
ultimately affecting gene regulatory functions and causing
disease. Age-related alteration of methylation status is a
global phenomenon, not necessarily limited to particular
disease susceptibility genes. Another study examined the
methylation changes in 807 arbitrarily selected genes from
two cohorts from Utah and Iceland, taking DNA samples
at two timepoints from each subject, spaced either 11 or
16 years apart. In these two populations, they observed
time-dependent changes in global DNA methylation
within the same individual, with 8% to 10% of individuals
in showing changes that were greater than 20 percent; both
gains and losses of methylation were detected.
77 Similarly,
the Boston Normative Aging Study measured DNA
methylation in the blood of 718 elderly subjects (55 to 92
years of age) over a span of 8 years. A progressive loss of
DNA methylation in repetitive elements was found, par-
ticularly in Alu repeats, and this linear decline highly cor-
related with time since the first measurement.
78A seem-
ingly innocuous early-life epigenetic change in some
critical gene involved in AD etiology, for example, the
amyloid precursor protein (APP) locus, could potentially
become pathologic when subjected to epigenetic drift as
the subject ages. Although the molecular mechanisms
leading to early-life methylation disturbances have not yet
been identified, the possibility of early epimutation and
epigenetic drift should not be ignored as an etiological can-
didate for LOAD. 
Autism spectrum disorders
Autism and related developmental disorders, such as
Asperger’s and Rett syndromes, fall under the broader
class of autism spectrum disorders (ASD), where “spec-
trum” reflects the observed continuum of severity or
impairment experienced. These disorders become appar-
ent in young children and persist into adulthood, with
deficits in social cognition regarded as the most charac-
teristic feature of ASD, leading to restrictions in social
communication.
79While autism itself is believed to have
a particularly strong inherited basis relative to other
developmental psychiatric syndromes,
80 DNA sequence
factors in the etiology of ASD are still largely unknown.
81
Evidence supports a contribution of imprinted genes in
ASD, as well as paternal transmission (reviewed in ref
82), and perhaps the combination of this information
and the lack of identified genetic markers will stimulate
future epigenetic and epigenomic studies of ASD. 
Rett syndrome (RTT), a division of ASD, has been
extensively studied and arises from loss of function
mutations at the locus for methyl-CpG-binding protein-
2 (MeCP2), a transcriptional repressor that silences
methylated genes
83 and may participate in RNA splic-
ing.
84 Mouse models have been very useful in delineat-
ing the relationship between disturbances to MeCP2 and
the disease.
85 In mice, deletion of MeCP2 mimics RTT
syndrome, leading to locomotor impairments and reduc-
tions in brain size.
86,87 Mice with a truncated MeCP2 pro-
tein, similar to that of RTT patients, developed many
features of RTT, such as tremors, motor impairments,
hypoactivity, increased anxiety-related behavior,
seizures, kyphosis, and stereotypic forelimb motions;
these mice also presented hyperacetylation on histone
H3,
88 illustrating that chromatin abnormalities exist in
this disorder. In astrocytes cultured from a mouse model
of RTT, MeCP2 deficiency causes significant abnormal-
ities in BDNF regulation, cytokine production, and neu-
ronal dendritic induction. Whereas previous experiments
have only focused on neurons, this evidence suggests
that astrocytes may also represent therapeutic targets for
RTT.
89
The classic form of autism also appears to be connected
to MeCP2 expression. Coding mutations affecting the
protein are rarely detected in autism, but significantly
increased MeCP2 promoter methylation has been found
in autistic male frontal cortex compared with controls,
and this inversely correlated with protein expression
90;
aberrant promoter methylation at MeCP2 has also been
detected in female brain DNA.
91 Similarly, loss of
methyl-CpG binding protein 1 (MBD1), leads to autism-
like behavioral deficits in mice, namely reduced social
Basic research
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interaction, learning deficits, anxiety, defective sensory
motor gating, depression, and abnormal brain serotonin
activity.
92Also, a novel mutation has been discovered in
the Jumonji AT-rich interactive domain 1C (JARID1C)
gene of a child with autism. While very preliminary, this
discovery is interesting, as JARID1C is believed to be a
histone demethylase specific for di- and trimethylated
histone 3 lysine 4 (H3K4), as well as a transcriptional
repressor for the ASD-associated genes SCN2A,
CACNA1H, BDNF, and SLC18A1.
93 Finally, another
interesting hypothesis relating epigenetics to ASD con-
cerns the observation that autistic children exhibit
improved behavior communication during febrile
episodes.
94 It may be the case that fever restores the
modulatory functions of the intact, but dysregulated
locus coeruleus-noradrenergic (LC-NA) system that is
present in ASD. The fact that the state of the LC-NA
system can be switched back and forth, combined with
evidence that imprinted genes within the LC-NA are
tightly epigenetically regulated and susceptible to envi-
ronmental interference,
95 suggests that dynamic epige-
netic remodeling processes may regulate the malfunc-
tioning pathways in ASD.
96
Epigenetic treatment opportunities
Epigenetic drug strategies are currently employed to
treat a collection of cancer subtypes, and these medica-
tions are now being considered in the treatment of psy-
chiatric disease, as well. The DNMT inhibitor, doxoru-
bicin, has been used to increase reelin and GAD67
expression in neuronal precursor cells, and it was shown
that reelin gene expression correlated with the dissocia-
tion of DNMT1 and MeCP2 from its promoter, as well as
an increased level of histone H3 acetylation.
97 Other stud-
ies have shown that HDAC inhibition enhances learning
and memory following neurodegeneration induced by
traumatic brain injury,
98 and also shows some therapeu-
tic efficacy in rodent models of neurodegenerative con-
ditions, such as Huntington’s disease,
99 multiple sclero-
sis,
100 and Parkinson’s disease.
101 One of the downstream
effects of HDAC inhibition is upregulation of p21,
102 a
cyclin-dependent kinase inhibitor that appears to play an
important protective role against oxidative stress and
DNA damage.
103Valproate, a compound utilized for its
anticonvulsant and mood-stabilizing properties, also
exhibits HDAC activity and has been successfully imple-
mented as a treatment for epilepsy,
104 BD,
105 and, less
commonly, SZ.
106 Like valproate, it has been discovered
that several drugs have previously unknown epigenetic
modifying properties, and the list continues to grow.
While such medications are promising, their pleiotropy,
transient effects, and nonspecific alterations to the entire
epigenome limit them for the time being. 
A substantial challenge to the field of epigenomics of
psychiatric and other diseases involves the identification
and verification of inhibitors for specific histone-modi-
fying enzymes. Once developed, these compounds should
provide higher therapeutic efficiency versus the nonspe-
cific therapeutics that are currently in use, such as
suberoylanilide hydroxamic acid (SAHA). The develop-
ment of small, targeted molecules to specific disease-
causing epimutations may resolve some of these issues
but, of course, the molecules themselves must first be
identified. Alternately, discovery of the downstream
effects of epimutations in vivo may nominate particular
proteins, to which drug interventions can be applied in
a more traditional style, using molecules to exert agonis-
tic and antagonistic effects on the protein products of epi-
genetically misregulated genes. Knowledge of the three
dimensional structures of DNA- and histone-modifying
enzymes is mounting and, through the use of fragment-
based drug design and ligand motif-based libraries,
107 vir-
tual screening technologies may soon become a feasible
option. In the search for target-specific ligands, high-
throughput screening of small organic molecule libraries
is a useful tool.
108A recent study utilized a 125 000 small
molecule library to screen for specific inhibitors against
histone lysine methyltransferases (HMTases). The com-
pound discovered was BIX-01294 (diazepinquinazolin-
amine derivative), an incredibly specific inhibitor of the
target enzyme, euchromatic G9a HMTase, that was able
to significantly lower promoter-proximal H3K9me2
marks in mouse embryonic stem cells.
109
In addition to small molecules, RNA and proteins may
also be utilized in the design of effective epigenetic
drugs. One strategy focuses on RNA interference
(RNAi), in which endogenously produced small inter-
fering RNAs (siRNAs) are incorporated into an RNA-
induced silencing complex (RISC) that targets and
destroys homologous mRNA, thus preventing protein
production.
110 A siRNA with the ability to knock down
beta-secretase (BACE1) in Huntington’s and AD has
been developed, as has one against the SCA1 gene in
spinocerebellar ataxia.
111 However, before these RNAs
can become effective treatment options, the issues of
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delivery, and inhibition of microRNA (miRNA) must
first be resolved. Although the exact mechanisms by
which RNAi affects local chromatin structure, gene
silencing, and heterochromatin assembly is unknown,
112
it still holds much promise as a therapeutic technique.
Another promising technology utilizes zinc-finger pro-
teins (ZFPs), which can recognize specific DNA
sequences and bind to short stretches of DNA (~9–18
basepairs), depending on their particular domains.
113This
feature could theoretically allow targeted ZFPs, attached
to a DNA- or histone-modifying enzyme,
114 to bind an
epimutated site and permit the enzyme to correct the
misregulation at that location alone. The damaging
global epigenetic effects observed with current drugs
would not occur, in this case.
The ability to target etiological disease epimutations and
identify epigenetic biomarkers for psychiatric diseases
would be another incredibly beneficial development.
Biotechnologies are advancing at an amazing rate, and
already allow for genome-wide detection of the patterns
of DNA methylation and histone modifications. Fully
mapped epigenomes in different tissues and cells will
facilitate the discovery of disease epimutations and the
mechanisms of their pathological action, thus providing
the basis for etiological treatment. 
Concluding remarks
The role of epigenetic mechanisms in psychiatric diseases
is only beginning to solidify, but it is already evident in
major psychosis, AD, ASD, and several other conditions
not described in this review, such as Rubinstein-Taybi
syndrome,
115 addiction,
116,117 Huntington’s disease,
118 and
Fragile X syndrome.
119 Maintenance of DNA methylation
and histone modifications is crucial for normal neurode-
velopment and functioning of the brain—dysregulation
of these components is highly deleterious to the subject
and can predispose to any of the aforementioned disease
phenotypes. Previous studies of psychiatric conditions
have concentrated on the contributions of genetic and
environmental factors but, while DNA sequence and
external influences may play an important role in disease
etiology, the impact of gene regulation via epigenetic
mechanisms on neural function also cannot be ignored.
Rather, the interplay between epigenetics, DNA
sequences, and environment should become the focus of
future work, adopting such concepts as differentially
methylated “epi-alleles”
120 and environmental effects on
DNA methylation and chromatin modifications.
2As tech-
nologies advance, next-generation sequencing and com-
prehensive microarrays will become much more afford-
able, allowing researchers to perform larger, more
in-depth epigenomic studies. Perhaps, in the near future,
identification of epigenetic biomarkers and operational-
ization of new, effective diagnostics and treatments will
become feasible for psychiatric and various other com-
plex diseases. ❏
Acknowledgements: This project was supported by the National Institute
of Mental Health (R01 MH074127; R01 MH088413), and the Canadian
Institutes for Health and Research (CIHR). CP is a CIHR Graduate Fellow, and
AP is Senior Fellow, of the Ontario Mental Health Foundation.
Basic research
32
REFERENCES
1. Henikoff S, Matzke MA. Exploring and explaining epigenetic effects.
Trends Genet. 1997;13:293-295.
2. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming
by maternal behavior. Nat Neurosci. 2004;7:847-854.
3. Riggs AD, Xiong Z, Wang L, LeBon JM. Methylation dynamics, epige-
netic fidelity and X chromosome structure. Novartis Found Symp.
1998;214:214-25; discussion 25-32.
4. Richards EJ. Inherited epigenetic variation--revisiting soft inheritance.
Nat Rev Genet. 2006;7:395-401.
5. Kaminsky ZA, Tang T, Wang SC, et al. DNA methylation profiles in
monozygotic and dizygotic twins. Nat Genet. 2009;41:240-245.
6. Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the
genome integrates intrinsic and environmental signals. Nat Genet.
2003;33(suppl):245-254.
7. Davey CA, Sargent DF, Luger K, Maeder AW, Richmond TJ. Solvent
mediated interactions in the structure of the nucleosome core particle at
1.9 a resolution. J Mol Biol. 2002;319:1097-1113.
8. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcyto-
sine is present in Purkinje neurons and the brain. Science. 2009;324:929-930.
9. Margueron R, Trojer P, Reinberg D. The key to development: inter-
preting the histone code? Curr Opin Genet Dev. 2005;15:163-176.
10. Thiagalingam S, Cheng KH, Lee HJ, et al. Histone deacetylases: unique
players in shaping the epigenetic histone code. Ann N Y Acad Sci.
2003;983:84-100.
11. Klose RJ, Zhang Y. Regulation of histone methylation by demethylim-
ination and demethylation. Nat Rev Mol Cell Biol. 2007;8:307-318.
12. Nicholson TB, Chen T. LSD1 demethylates histone and non-histone pro-
teins. Epigenetics. 2009;4:129-132.
13. Reiss D, Plomin R, Hetherington EM. Genetics and psychiatry: an unher-
alded window on the environment. Am J Psychiatry. 1991;148:283-291.
14. Petronis A, Gottesman II, Kan P, et al. Monozygotic twins exhibit
numerous epigenetic differences: clues to twin discordance? Schizophr Bull.
2003;29:169-178.
15. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the
lifetime of monozygotic twins. Proc Natl Acad Sci U S A. 2005;102:10604-10609.
16. Seeman MV. Psychopathology in women and men: focus on female
hormones. Am J Psychiatry. 1997;154:1641-1647.
17. Auger AP, Jessen HM. Corepressors, nuclear receptors, and epigenetic
factors on DNA: a tail of repression. Psychoneuroendocrinology. 2009;34 (suppl
1):S39-S47.
DCNS_44_5.qxd:DCNS#44  10/03/10  1:44  Page 32Epigenetic approaches to psychiatric disorders - Ptak and Petronis Dialogues in Clinical Neuroscience - Vol 12 . No. 1 . 2010
33
Aproximaciones epigenéticas a los 
trastornos psiquiátricos
Las enfermedades psiquiátricas determinan un
enorme costo para los individuos afectados, sus cui-
dadores y el sistema de atención de salud. Aunque
existe evidencia de un fuerte componente heredita-
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curso fluctuante de la enfermedad. Recientemente
las tecnologías experimentales han avanzado de
manera significativa, permitiendo estudios a fondo
del epigenoma y de su papel en el mantenimiento
de las funciones genómicas normales, como también
en la etiopatogenia de las enfermedades. En este
artículo se presenta una explicación epigenética para
muchas características de la enfermedad psiquiátrica,
se revisa la literatura actual acerca de los mecanismos
epigenéticos involucrados en las principales psicosis,
la Enfermedad de Alzheimer, y los trastornos del
espectro autístico, y se describen algunas líneas a
futuro en el campo de la epigenómica psiquiátrica. 
Approches épigénétiques des troubles 
psychiatriques
Les maladies psychiatriques pèsent considérable-
ment sur les individus atteints, leurs soignants et sur
le système de santé. Même s’il existe des arguments
pour une forte héritabilité de beaucoup de ces
troubles, les efforts portés sur l’identification des
causes liées à une séquence ADN n’ont pas été très
productifs et très peu de traitements pharmacolo-
giques sont disponibles. De nombreuses caractéris-
tiques des maladies psychiatriques concordent avec
une dysrégulation épigénétique, comme une dis-
cordance entre jumeaux monozygotes, un début
tardif, des effets liés au sexe et aux origines paren-
tales et une évolution fluctuante de la maladie. Ces
dernières années, des avancées significatives des
technologies expérimentales ont permis d’étudier
en profondeur l’épigénome et son rôle dans le
maintien des fonctions génomiques normales
comme dans l’étiopathogenèse de la maladie. Nous
présentons dans cet article une explication épigé-
nétique pour de nombreuses caractéristiques des
maladies psychiatriques, nous analysons la littéra-
ture actuelle sur les mécanismes épigénétiques
impliqués dans les psychoses majeures, la maladie
d’Alzheimer et les troubles autistiques et nous don-
nons quelques perspectives dans le domaine de
l’épigénomique psychiatrique.
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